Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | USP19 | O94966 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL554798 | 0.89 | IL1B (0.38) | SMYD2SMN1; SMN2HCRTR2DPP4LMNA | |
| SCHEMBL554333 | 0.89 | IL1B (0.38) | SMYD2SMN1; SMN2HCRTR2DPP4LMNA | |
| SCHEMBL554334 | 0.89 | IL1B (0.38) | SMYD2SMN1; SMN2HCRTR2DPP4LMNA | |
| SCHEMBL29080085 | 0.80 | SMYD2 (0.39) | SMYD2CYP3A4SMN1; SMN2HTTLMNA | |
| SCHEMBL21987485 | 0.80 | SMYD2 (0.35) | SMYD2CYP3A4SMN1; SMN2HTTLMNA | |
| SCHEMBL19948678 | 0.80 | KCNH2 (0.39) | — | |
| SCHEMBL17895160 | 0.79 | SMYD2 (0.38) | SMYD2CYP3A4SMN1; SMN2HTTHCRTR1 | |
| SCHEMBL4516524 | 0.79 | SMYD2 (0.41) | SMYD2CYP3A4SMN1; SMN2HTT | |
| SCHEMBL4516522 | 0.79 | SMYD2 (0.41) | SMYD2CYP3A4SMN1; SMN2HTT | |
| SCHEMBL21987604 | 0.78 | SMYD2 (0.35) | SMYD2CYP3A4SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016109221-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| EP-2601177-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | SMYD2 2749/4885CYP3A4 1309/4885PDK1 347/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | SMYD2 2749/4885CYP3A4 1309/4885PDK1 347/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | SMYD2 2749/4885CYP3A4 1309/4885PDK1 347/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | SMYD2 692/4885CYP3A4 3076/4885PDK1 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.